• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.

作者信息

Winthrop Kevin L, Citera Gustavo, Gold David, Henrohn Dan, Connell Carol A, Shapiro Andrea B, Shi Harry, Onofrei Alina M, Pappas Dimitrios A, Schulze-Koops Hendrik

机构信息

Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.

Section of Rheumatology, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina.

出版信息

Ann Rheum Dis. 2021 Jan;80(1):134-136. doi: 10.1136/annrheumdis-2020-218992. Epub 2020 Oct 12.

DOI:10.1136/annrheumdis-2020-218992
PMID:33046447
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7788057/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6c2/7788057/f070b94bed13/annrheumdis-2020-218992f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6c2/7788057/f070b94bed13/annrheumdis-2020-218992f01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d6c2/7788057/f070b94bed13/annrheumdis-2020-218992f01.jpg

相似文献

1
Age-based (<65 vs ≥65 years) incidence of infections and serious infections with tofacitinib versus biological DMARDs in rheumatoid arthritis clinical trials and the US Corrona RA registry.在类风湿关节炎临床试验及美国Corrona类风湿关节炎注册研究中，托法替布与生物性改善病情抗风湿药相比，基于年龄（<65岁与≥65岁）的感染及严重感染发生率。
Ann Rheum Dis. 2021 Jan;80(1):134-136. doi: 10.1136/annrheumdis-2020-218992. Epub 2020 Oct 12.
2
Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.比较类风湿关节炎患者一线肿瘤坏死因子抑制剂与非肿瘤坏死因子抑制剂生物制剂和靶向合成药物的疗效：来自一项大型美国注册研究的结果。
Ann Rheum Dis. 2021 Jan;80(1):96-102. doi: 10.1136/annrheumdis-2020-217209. Epub 2020 Jul 21.
3
Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.托法替布，一种口服的 Janus 激酶抑制剂，用于治疗拉丁美洲类风湿关节炎患者：3 期和长期扩展研究的汇总疗效及安全性分析
Reumatol Clin. 2017 Jul-Aug;13(4):201-209. doi: 10.1016/j.reuma.2016.04.010. Epub 2016 Jun 15.
4
Tofacitinib, an oral Janus kinase inhibitor, in patients from Mexico with rheumatoid arthritis: Pooled efficacy and safety analyses from Phase 3 and LTE studies.托法替布，一种口服的 Janus 激酶抑制剂，用于墨西哥类风湿关节炎患者：3 期和长期扩展（LTE）研究的汇总疗效和安全性分析。
Reumatol Clin (Engl Ed). 2019 Jan-Feb;15(1):43-53. doi: 10.1016/j.reuma.2017.04.006. Epub 2017 May 25.
5
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
6
Biologics or tofacitinib for rheumatoid arthritis in incomplete responders to methotrexate or other traditional disease-modifying anti-rheumatic drugs: a systematic review and network meta-analysis.生物制剂或托法替布用于对甲氨蝶呤或其他传统改善病情抗风湿药物反应不完全的类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2016 May 13;2016(5):CD012183. doi: 10.1002/14651858.CD012183.
7
Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.瑞士观察性队列类风湿关节炎患者中抗肿瘤坏死因子药物、具有替代作用模式的生物制剂和托法替尼的疗效比较。
RMD Open. 2020 May;6(1). doi: 10.1136/rmdopen-2020-001174.
8
Comparison of the efficacy and safety of tofacitinib and upadacitinib in patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials.比较托法替布和乌帕替尼在活动性类风湿关节炎患者中的疗效和安全性：一项基于随机对照试验的贝叶斯网状荟萃分析。
Int J Rheum Dis. 2019 Aug;22(8):1563-1571. doi: 10.1111/1756-185X.13616. Epub 2019 Jun 18.
9
Effectiveness of tofacitinib versus tumor necrosis factor inhibitors and in those receiving tofacitinib as different lines of therapy in patients with rheumatoid arthritis: results from the United States CorEvitas Rheumatoid Arthritis Registry.托法替布与肿瘤坏死因子抑制剂相比的有效性，以及类风湿关节炎患者接受不同治疗线托法替布治疗的有效性：来自美国CorEvitas类风湿关节炎注册研究的结果
Clin Rheumatol. 2025 Feb;44(2):635-648. doi: 10.1007/s10067-024-07245-3. Epub 2024 Dec 20.
10
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者：一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.

引用本文的文献

1
Management of Late-Onset Rheumatoid Arthritis with Treat-to-Target Strategy.采用达标治疗策略管理晚发型类风湿关节炎
Drugs Aging. 2025 May;42(5):413-433. doi: 10.1007/s40266-025-01195-4. Epub 2025 Apr 9.
2
Low-Dose Glucocorticoids in Older Patients with Rheumatoid Arthritis: What Does the Evidence Say?老年类风湿关节炎患者应用小剂量糖皮质激素：证据说了什么？
Drugs Aging. 2024 Aug;41(8):641-652. doi: 10.1007/s40266-024-01133-w. Epub 2024 Jul 27.
3
Geographical Differences in the Safety and Efficacy of Tofacitinib Versus TNFi: A Post Hoc Analysis of ORAL Surveillance.

本文引用的文献

1
Risk of admission to hospital for serious infection after initiating tofacitinib versus biologic DMARDs in patients with rheumatoid arthritis: a multidatabase cohort study.类风湿关节炎患者起始使用托法替布与生物性改善病情抗风湿药后因严重感染入院的风险：一项多数据库队列研究
Lancet Rheumatol. 2020 Feb;2(2):e84-e98. doi: 10.1016/S2665-9913(19)30137-7. Epub 2020 Jan 13.
2
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial.托法替布单药治疗、托法替布联合甲氨蝶呤与阿达木单抗联合甲氨蝶呤治疗类风湿关节炎患者的疗效和安全性（ORAL Strategy）：一项 IIIb/IV 期、双盲、头对头、随机对照临床试验。
Lancet. 2017 Jul 29;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Epub 2017 Jun 16.
3
托法替布与肿瘤坏死因子抑制剂安全性和疗效的地理差异：ORAL Surveillance研究的事后分析
Rheumatol Ther. 2024 Oct;11(5):1217-1235. doi: 10.1007/s40744-024-00693-y. Epub 2024 Jul 26.
4
Selective JAK-Inhibitors in Spondyloarthritis.脊柱关节炎中的选择性JAK抑制剂
Mediterr J Rheumatol. 2024 Mar 30;35(Suppl 1):27-36. doi: 10.31138/mjr.311023.sji. eCollection 2024 Mar.
5
Selectivity, efficacy and safety of JAKinibs: new evidence for a still evolving story.JAKinib 的选择性、疗效和安全性：一个仍在不断发展的故事的新证据。
Ann Rheum Dis. 2024 Jan 11;83(2):139-160. doi: 10.1136/ard-2023-223850.
6
Serious infection risk of tofacitinib compared to biologics in patients with rheumatoid arthritis treated in routine clinical care.与生物制剂相比，托法替布在常规临床治疗的类风湿关节炎患者中具有严重感染风险。
Sci Rep. 2023 Oct 18;13(1):17776. doi: 10.1038/s41598-023-44841-w.
7
Clinical scenarios-based guide for tofacitinib in rheumatoid arthritis.类风湿关节炎中托法替布基于临床病例的指南
Ther Adv Chronic Dis. 2023 Jun 20;14:20406223231178273. doi: 10.1177/20406223231178273. eCollection 2023.
8
Alopecia Areata: Burden of Disease, Approach to Treatment, and Current Unmet Needs.斑秃：疾病负担、治疗方法及当前未满足的需求
Clin Cosmet Investig Dermatol. 2023 Mar 31;16:803-820. doi: 10.2147/CCID.S376096. eCollection 2023.
9
Choosing the Appropriate Target for the Treatment of Psoriatic Arthritis: TNFα, IL-17, IL-23 or JAK Inhibitors?为银屑病关节炎选择合适的治疗靶点：肿瘤坏死因子α、白细胞介素-17、白细胞介素-23还是JAK抑制剂？
Mediterr J Rheumatol. 2022 Apr 15;33(Suppl 1):150-161. doi: 10.31138/mjr.33.1.150. eCollection 2022 Mar.
10
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial.托法替布与肿瘤坏死因子抑制剂治疗类风湿关节炎患者的感染：来自开放性、随机对照 ORAL Surveillance 试验的结果。
Ann Rheum Dis. 2022 Nov;81(11):1491-1503. doi: 10.1136/ard-2022-222405. Epub 2022 Aug 3.
Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.托法替尼或阿达木单抗与安慰剂治疗类风湿关节炎的比较。
N Engl J Med. 2012 Aug 9;367(6):508-19. doi: 10.1056/NEJMoa1112072.
4
Use of a disease risk score to compare serious infections associated with anti-tumor necrosis factor therapy among high- versus lower-risk rheumatoid arthritis patients.使用疾病风险评分比较高风险与低风险类风湿关节炎患者使用抗肿瘤坏死因子治疗相关的严重感染。
Arthritis Care Res (Hoboken). 2012 Oct;64(10):1480-9. doi: 10.1002/acr.21805.
5
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.口服JAK抑制剂托法替布（CP-690,550）或阿达木单抗单药治疗与安慰剂对比，用于对改善病情抗风湿药反应不足的活动性类风湿关节炎患者的IIb期剂量范围研究。
Arthritis Rheum. 2012 Mar;64(3):617-29. doi: 10.1002/art.33383.
6
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly.抗 TNF 治疗与类风湿关节炎患者严重感染的风险增加相关，尤其是在治疗的前 6 个月：英国风湿病学会生物制剂注册处的最新结果，特别强调了老年人的风险。
Rheumatology (Oxford). 2011 Jan;50(1):124-31. doi: 10.1093/rheumatology/keq242. Epub 2010 Jul 31.